Actavis plans to change name to Allergan after acquisition closes

Will retain Actavis name for certain geographic regions and product portfolios

Brent Saunders: We will operate the new Allergan as one company with one culture

Actavis plans to change its name to Allergan once the US$66m acquisition of the US company is finalised.

Dublin-based Actavis says it intends to use Allergan as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for certain geographic regions and product portfolios.

Brent Saunders, Chief Executive of Actavis, says the merger of the two companies will create a 'dynamic new breed of company – a leader in growth pharma'.

'For more than 65 years, the Allergan name has represented innovation in branded pharmaceuticals, a commitment to bringing the best medicine to life and a strong partnership with physicians,' he said.

We will operate the new Allergan as one company with one culture

'The Actavis name has represented our global commitment to leadership in generic, branded generic and OTC pharmaceuticals and to increased access to more affordable prescription medicine for consumers around the world.

'Together, our combined company will be equally focused on developing new medicines that meet unmet medical needs in critical therapeutic categories, as well as increasing global access to high quality, affordable medicines.'

Saunders added: 'Although we will have distinct identities to our various customers and in select geographies, we will operate the new Allergan as one company with one culture, led by an industry-leading unified senior management team.'

Actavis will ask shareholders to approve its intention to adopt the Allergan name at its Annual General Meeting of Shareholders later this year.

Companies